Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11416
Date Received: 22/04/2026
Summary:
Request in relation to personal information.
Date of Response: 23/04/2026
View Response: 11416.pdf
Freedom of Information Request Reference: 11407
Date Received: 20/04/2026
Summary:
Request in relation to personal information.
Date of Response: 21/04/2026
View Response: 11407.pdf
Freedom of Information Request Reference: 11394
Date Received: 15/04/2026
Summary:
1. What are the current costs of running the Loanesk Ward in Midlothian Community Hospital with 16 beds 2. What will be the savings created by reducing the number of beds to 10 and relocating the palliative care unit to the rehabilitation ward 3. What will happen to the patients currently using the rehabilitation ward 4. What will be the costs of maintaining rehab care elsewhere and will this represent a saving or an increase in costs for this service?
Date of Response: 07/05/2026
View Response: 11394.pdf
Freedom of Information Request Reference: 11389
Date Received: 13/04/2026
Summary:
Q1. How many patients has your Trust treated (for any medical condition) in the past 3 months with the following drugs: •Alprolix •BeneFIX •Haemate P •Idelvion •Refixia •Rixubis •Veyvondi •Voncento •Wilate •Willfact Q2. How many patients have been treated in the past 3 months with: •Marstacimab for Haemophilia B ONLY •Hemgenix for Haemophilia B ONLY •Desmopressin for Von Willebrand Disease ONLY •Tranexamic Acid for Von Willebrand Disease ONLY Q3. Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment: •Prophylactically •During surgery •On demand to treat bleeding episodes Q4. Of the patients that were treated with Voncento in the past 3 months, how many patients received treatment: •Prophylactically •During surgery •On demand to treat bleeding episodes Q5. How many patients are registered with your trust for the following diseases: •Haemophilia B •Von Willebrand Disease •Von Willebrand Disease - paediatric patients (age 17 or under)
Date of Response: 06/05/2026
View Response: 11389.pdf
Freedom of Information Request Reference: 11386
Date Received: 13/04/2026
Summary:
1. Is Basic Life Support course mandatory for the medical professionals working for the Health Board? 2. How many courses per year does your Resus Training Department deliver? 3. What percentage of doctors/nurses/midwives and other allied health professionals have done BLS training in the last 1 year? 4. What percentage of your medical personnel have profession specific Advanced Life Support (ALS) training? 5. What is the required frequency for mandatory BLS training? 6. What strategies or measures has the trust adopted to encourage annual BLS training for medical professionals with patient facing duties ( no pay progression if mandatory training not completed, departmental sessions, ESR alerts, managerial supervision of mandatory training etc)? 7. Does the organisation require resus teams to have Advanced Life Support training?
Date of Response: 04/05/2026
View Response: 11386.pdf
Freedom of Information Request Reference: 11383
Date Received: 10/04/2026
Summary:
From 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with off-framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum AHP/HSS staffing Please provide a further breakdown for locum AHP/HSS staffing by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum AHP/HSS staffing for the period 1st January 2026 to 31st March 2026 Please confirm the framework you utilise for AHP/HSS agency staff.
Date of Response: 06/05/2026
View Response: 11383.pdf
Freedom of Information Request Reference: 11382
Date Received: 09/04/2026
Summary:
Q1. Within your trust, how many patients currently have a diagnosis for: •Fabry(-Anderson) disease (ICD10 code E75.21) •Gaucher disease (ICD10 code E75.22) •Pompe disease (ICD10 Code E74.02) •Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) •Hunter syndrome (MPS II) (ICD10 code E76.1) Q2. Of the patients above, how many patients have been newly diagnosed within the past 3 months for: •Fabry(-Anderson) disease (ICD10 code E75.21) •Gaucher disease (ICD10 code E75.22) •Pompe disease (ICD10 Code E74.02) •Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) •Hunter syndrome (MPS II) (ICD10 code E76.1) Q3. How many patients have been treated in the last 3 months with the following products: •Replagal (agalsidase alfa) •Fabrazyme (agalsidase beta) •Galafold (migalastat) •Elfabrio (pegunigalsidase alfa) •VPRIV (velaglucerase alfa) •Cerezyme (imiglucerase) •Cerdelga (eliglustat) •Zavesca (miglustat) •Myozyme (alglucosidase alfa) •Nexviadyme (avalglucosidase alfa) •Pombiliti + Opfolda (cipaglucosidase alfa + miglustat) Q4. Do you participate in any clinical trials for Fabry(-Anderson) disease? If so, can you please provide the name of each trial along with the number of patients taking part? Q5. Do you participate in any clinical trials for Gaucher disease? If so, can you please provide the name of each trial along with the number of patients taking part?
Date of Response: 06/05/2026
View Response: 11382.pdf
Freedom of Information Request Reference: 11380
Date Received: 09/04/2026
Summary:
From January 2024-March 2026, how many candidates who applied for NHS Lothian jobs under the Guaranteed Interview Scheme set out by the UK Government, were offered an interview?
Date of Response: 06/05/2026
View Response: 11380.pdf
Freedom of Information Request Reference: 11377
Date Received: 08/04/2026
Summary:
I am requesting aggregated information about brain tumour resections carried out by your Trust and whether resected brain tumour tissue can be flash frozen to -80°C within 30 minutes of resection. Time period: Please provide the information below for the two most recent full years for which data is available. Definition: “Fresh-frozen” means brain tumour tissue that is snap frozen and stored at -80°C or colder. Questions: 1. Does your Trust perform neurosurgical brain tumour surgery or biopsy on-site? (Yes/No) 2. For patients undergoing brain tumour surgery or biopsy under your Trust’s care, does the usual clinical pathway provide access to facilities that place brain tumour tissue into a fresh-frozen state within at least 30 minutes of excision? (Yes / No / Not applicable) 3. If Yes, is this access: a) On-site within your Trust b) Off-site/external c) Both 4. If off-site/external, please name the organisation or type of facility used. 5. For each year, approximately how many patients underwent surgery or biopsy for a brain tumour / brain cancer at your Trust? 6. For each year, approximately how many brain tumour tissue specimens were handled by your pathology service? 7. For each year, how many of these specimens were fresh-frozen: a) within any time frame? b) within 30 minutes?
Date of Response: 06/05/2026
View Response: 11377.pdf
Freedom of Information Request Reference: 11376
Date Received: 08/04/2026
Summary:
Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? •Altuvoct •Advate •Adynovi •Elocta •Esperoct •Factor Eight Inhibitor Bypass Activity (FEIBA) •Hemlibra (standalone) •Hemlibra in combination with any Factor VIII •NovoEight •NovoSeven RT •Nuwiq •Obizur •Refacto AF •Any other products •Marstacimab •Cevenfacta Q3. For patients treated with Advate in the last three months, please provide: •The number of haemophilia A patients treated prophylactically •The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? •Altuvoct •Advate •Adynovi •Elocta •Esperoct •Factor Eight Inhibitor Bypass Activity (FEIBA) •Hemlibra (standalone) •Hemlibra in combination with any Factor VIII •NovoEight •NovoSeven RT •Nuwiq •Obizur •Refacto AF •Any other products •Marstacimab •Cevenfacta
Date of Response: 05/05/2026
View Response: 11376.pdf
Freedom of Information Request Reference: 11374
Date Received: 07/04/2026
Summary:
Please can we request freedom of information for the amputation figures across Scotland. If we can have it broken down by region and also type for instance particularly interested in leg, arm, hand, foot amputations. If we can have figures for the past 3 years that would be most helpful.
Date of Response: 01/05/2026
View Response: 11374.pdf
Freedom of Information Request Reference: 11372
Date Received: 01/04/2026
Summary:
Question 1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products: •Abrocitinib •Acitretin •Alitretinoin •Azathioprine •Baricitinib •Ciclosporin •Dupilumab •Lebrikizumab •Methotrexate •Mycophenolate mofetil •Pimecrolimus •Phototherapy (UVB or PUVA) - for Atopic Dermatitis only •Tacrolimus ointment •Tralokinumab •Upadacitinib •Nemolizumab Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department •Abrocitinib •Baricitinib •Dupilumab •Lebrikizumab •Tralokinumab •Upadacitinib •Nemolizumab *Patients are considered ‘new patients initiated’ on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation. e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025) Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: •6 months to 5 •Age 6-11 •Age 12-17 •Age 18 and above Question 4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products: •Dupilumab •Nemolizumab
Date of Response: 01/05/2026
View Response: 11372.pdf
Freedom of Information Request Reference: 11371
Date Received: 01/04/2026
Summary:
In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with off framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st January 2026 to 31st March 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name Please confirm the total number of nursing shifts booked during this period for all agency nursing only, no bank staff nursing to be included (1st January 2026 to 31st March 2026) Please confirm the total number of nursing shifts booked above NHSE capped rates during this period for all agency nursing only, no bank staff nursing to be included (1st January 2026 to 31st March 2026) Please confirm the framework you utilise for nursing agency staff.
Date of Response: 01/05/2026
View Response: 11371.pdf
Freedom of Information Request Reference: 11369
Date Received: 01/04/2026
Summary:
Please provide the following recorded information relating to NHS-commissioned complex care at home and specialist community nursing services: 1. Total expenditure on complex care packages delivered at home (including NHS Continuing Healthcare (CHC) and non-CHC complex community health packages) for each of the last three full financial years and the current year to date. Please separate adults and children where the data is held. 2. The number of active complex care packages at home as at the most recent date available, broken down by: o Adults / Children o Broad clinical category where held (e.g. learning disabilities/autism, mental health, tracheostomy/ventilation/airway management, other clinically complex needs) 3. A list of all independent, private or voluntary sector providers commissioned for complex care at home or specialist community nursing packages in the period, including (where recorded): o Number of packages per provider o Approximate total spend per provider (or top 10 providers by value) o Whether provision was via full managed package, spot purchase, framework agreement, or rapid-response/temporary staffing 4. Details of any current framework agreements, block contracts or dynamic purchasing systems for complex home care / specialist nursing / rapid-response staffing, including: o Provider names o Contract start and end dates (or review/renewal dates) o Scope (e.g. 24/7 nursing, paediatric, LD/autism/MH, hospital discharge support) 5. The name, job title and contact details (email/telephone) of the commissioner or team lead responsible for sourcing complex care at home packages and rapid-response nursing support.
Date of Response: 30/04/2026
View Response: 11369.pdf
Freedom of Information Request Reference: 11368
Date Received: 30/03/2026
Summary:
For the last five calendar years (or the most recent five year period for which data is available): 1. The number of attendances at any of your emergency and urgent care services (including A&E, Emergency Department, Minor Injuries Unit and Urgent Treatment Centre) where the primary reason for attendance was a ring stuck on a finger. 2. For the attendances identified in Question 1, please provide a breakdown by: • Sex (male / female / other / unknown). • Age group (for example: 0–9, 10–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70+), or whatever age banding you use in your reporting.
Date of Response: 29/04/2026
View Response: 11368.pdf
Freedom of Information Request Reference: 11367
Date Received: 07/04/2026
Summary:
Please confirm if you operate a vendor management system for agency staff such as an MSP/neutral vendor/master vendor etc. If so, please can you name the below: -Company name -Contract start and end date -Framework utilised -Healthcare specialty used for, EG Doctors/Nursing/AHP/HSS/NMNC -Do you utilise a direct engagement model and the name of the model, eg Tempre/Own DE model etc Please confirm if you operate a vendor management system for bank staff. If so, please can you name the below: -Company name -Contract start and end date -Framework utilised -Healthcare specialty used for, EG Doctors/Nursing/AHP/HSS/NMNC
Date of Response: 30/04/2026
View Response: 11367.pdf
Freedom of Information Request Reference: 11366
Date Received: 07/04/2026
Summary:
I request the following information for adult combined ADHD/ASD neurodevelopmental assessments in NHS Lothian for the most recent 24 months: 1. Referral Numbers & Waiting Times o Total number of adult referrals for combined ADHD/ASD assessment. o Median, average, and longest waiting times from referral to assessment, broken down by HSCP area:  Edinburgh City  East Lothian  Midlothian  West Lothian 2. Urgent / Fast-Track Pathways o Number of adults assessed via urgent or fast-track pathways, if any. o Criteria used for prioritisation. 3. Community Team Involvement o Number of adults under Community Mental Health Teams (CMHTs) or Community Parental Mental Health Teams while awaiting assessment. o Average length of involvement while waiting. 4. Shared Care Prescribing Arrangements o Number of adults under shared care agreements for ADHD medication initiated or continued in the past 24 months. o Any delays in medication initiation attributable to waiting for the combined assessment. 5. Cross-Board Referrals o Number of adult referrals received from or sent to other NHS boards (East, West, Borders, Fife, etc.). o Waiting times for these out-of-board referrals. 6. Supporting Documentation o Copies of any internal reports, guidance, or policy documents summarising adult combined ADHD/ASD assessment pathways, waiting lists, or triage procedures in NHS Lothian.
Date of Response: 04/05/2026
View Response: 11366.pdf
Freedom of Information Request Reference: 11363
Date Received: 07/04/2026
Summary:
• The number of emergency: o CT Angio Aorta o CT Angio Aortic Arch and Carotids o CT Aorta Thoracic o CT Aorta Thoracic with contrast o CT Aorta Whole o CT Aorta Whole with contrast • Carried out each year between 1.1.16 and 31.12.25 • To avoid double counting, please identify by Count of Unique Accession Number or equivalent • The number of patients with a primary or secondary ICD-10 diagnosis of I-71.0 discharged dead each year between 1.1.16 and 31.12.25 with an emergency inpatient admission (Please do not include A&E discharge diagnosis). • The number of patients with a primary or secondary ICD-10 diagnosis of I-71.0 discharged dead each year between 1.1.16 and 31.12.25. All patients (Please do not include A&E discharge diagnosis)
Date of Response: 30/04/2026
View Response: 11363.pdf
Freedom of Information Request Reference: 11359
Date Received: 02/04/2026
Summary:
I was looking to make an FOI request regarding the number of elective operations cancelled at Royal Infirmary of Edinburgh due to transplant activity taking priority with the date raging from both 2024-2025 and 2025-2026. A further request is NHS Lothian's estimated running costs to run a single operating theatre for a 24 hour period that is considered fully staffed.
Date of Response: 01/05/2026
View Response: 11359.pdf
Freedom of Information Request Reference: 11358
Date Received: 01/04/2026
Summary:
I am seeking information regarding instances where the wrong person's body was released to families, funeral directors or undertakers. Please tell how many such cases there have been within the health board area since the year 2020. Please provide the relevant hospitals' names, the date of the incidents and the deceaseds' ages. Please also tell me how many complaints the health board has received regarding these matters over the time period.
Date of Response: 01/05/2026
View Response: 11358.pdf
Freedom of Information Request Reference: 11357
Date Received: 01/04/2026
Summary:
Please provide the following information for NHS Lothian services within the West Lothian area: 1. The number of delayed discharges where housing was a factor. 2. The average delay length. 3. The longest delay recorded I request that all information covers the period from 1 January 2025 to the present, and is provided in an electronic tabular format.
Date of Response: 01/05/2026
View Response: 11357.pdf
Freedom of Information Request Reference: 11356
Date Received: 27/03/2026
Summary:
With 2027 just 9 months away and Ferryfield not fit for purpose, what plans have NHS Lothian made to relocate the extremely vulnerable and complex patients currently cared for within the HBCCC unit? I would like to see all documents relating to this matter in the period from July 2023 to present.
Date of Response: 07/05/2026
View Response: 11356.pdf
Freedom of Information Request Reference: 11354
Date Received: 26/03/2026
Summary:
Does your NHS Board provide any mental health services for under 18 year olds (e.g. CAMHS)? If you do not, please reply stating that you do not provide mental health services for under 18 year olds and none of the other questions of this FOI are required as they are not relevant. If you do provide mental health services for under 18 year olds: • What is the age brackets for the mental health services for young people before they move to adult services (for example 0-18 year olds or 0-25 years old)? • What do you call this service (for example Child and Adolescent Mental Health Services (CAMHS) or if there is a specific name you use)? • What methods of referral do you accept (for example- referrals from GPs/schools)? • Are self referrals an option? If so what are the requirements (e.g. minimum age)? • What is your method of advising patients of appointments (e.g. text/post)? I would also like to request a blank document of the following forms: • The form used by GPs/schools to refer a young person • The form used if a young person is referring themselves • Any forms that are provided at the first appointment for the young person/parent to fill out in regards to contact information, preferences of methods of contact, who is attending the appointments etc • Any relevant forms to indicate who is attending the appointment/aware of the referral (young person/their guardian/both) and which of the two should be contacted and if there is a preference of contact method
Date of Response: 06/05/2026
View Response: 11354.pdf
Freedom of Information Request Reference: 11352
Date Received: 30/03/2026
Summary:
I would be grateful if you could provide figures for the number of inpatient / outpatient / day case appointments and any other NHS activity measurements that are available for: (a) June 15 last year (b) The May 5 bank holiday last year (c) The May 26 bank holiday last year
Date of Response: 29/04/2026
View Response: 11352.pdf
Freedom of Information Request Reference: 11351
Date Received: 25/03/2026
Summary:
Beginning from January 1, 2020 until March 25, 2026 I am requesting a breakdown of staff members at four NHS Lothian hospitals who have been suspended, sanctioned, or struck off for sexual misconduct. The four hospitals are the Royal Infirmary of Edinburgh, the Western General Hospital, the Royal Edinburgh, and the Royal Hospital for Children & Young People. Please provide: 1. The date the sanction went into effect 2. The general job title for the staff member (including but not limited to nurse, doctor, technician, administrative assistant, etc) 3. Whether the misconduct was perpetrated against another member of staff, a patient, or a member of the public who was visiting the hospital 4. For those members of staff who were suspended/sanctioned, please note whether they have returned to work at NHS Lothian as of March 25, 2026
Date of Response: 20/04/2026
View Response: 11351.pdf
Freedom of Information Request Reference: 11350
Date Received: 01/04/2026
Summary:
Total number of male nurses employed by you in the past 5 years. Total number of male nurses in each of these fields: Adult Children's Mental Health Learning Disability
Date of Response: 06/05/2026
View Response: 11350.pdf
Freedom of Information Request Reference: 11349
Date Received: 01/04/2026
Summary:
According to this NHS Inform page - Breast screening in Scotland | NHS inform - a woman undergoing a mammogram as part of the national screening programme will: "receive 1 of 3 results: • normal result • positive result • inconclusive result" 1. What criteria were applied in 2020 and 2023 and are applied now by the reporting radiologist to determine whether results are classified as normal, positive or inconclusive? 2. What national or professional guidance/criteria did/does the reporting radiologist refer to when making their determination? 3. If a patient were found to have "indeterminate calcification" on their first mammogram (age 50-53) undertaken during the screening process in September 2020, would this result in a normal, positive or inconclusive report? 4. If a patient were found to have "indeterminate calcification" on their second mammogram (age 53-56) undertaken during the screening process in July 2023, would this result in a normal, positive or inconclusive report? 5. If a patient had received a "positive" result in either September 2020 and/or July 2023, what would then happen have happened?
Date of Response: 29/04/2026
View Response: 11349.pdf
Freedom of Information Request Reference: 11348
Date Received: 01/04/2026
Summary:
For the period from 1 September 2024 to 1 April 2026: 1. Are injectable pharmacological treatments for overweight and obesity currently being initiated for patients as part of routine services commissioned or delivered by your organisation? If so, please identify which medication(s) are currently used as first-line injectable pharmacological therapy for overweight and obesity within commissioned services. 2. What are the eligibility criteria for patients to access injectable pharmacological treatments for overweight and obesity within your organisation? Where these criteria are already published online, please provide the relevant link and confirm whether the published criteria are currently being applied in practice. 3. Please confirm whether the model of care through which these treatments are (or will be) delivered: o Directly from general practice o Primary care-led weight management service (e.g. GP or pharmacist-led weight management service, community weight management hub, etc.) o Tier 3 specialist weight management services o Other (please specify). 4. Please confirm whether the relevant pathway within your organisation is currently: o operational and accepting referrals o operational but limited (e.g. pilot sites) o approved but not yet implemented o currently under development. 5. Please provide copies of any key or current clinical pathways, service specifications, prescribing guidance, or referral criteria relating to the use of injectable pharmacological treatments for overweight and obesity, if held.
Date of Response: 23/04/2026
View Response: 11348.pdf
Freedom of Information Request Reference: 11347
Date Received: 01/04/2026
Summary:
HAE & IG questionnaire HAE: Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]: Berinert (Human C1-esterase inhibitor) Cinryze (Human C1-esterase inhibitor) Orladeyo (Berotralstat) Takhzyro (Lanadelumab) Ruconest (Recombinant human C1-esterase inhibitor) Firazyr (Icatibant injection) Icatibant - any brand except Firazyr IG: Q2. In the past 3 months how many patients have received the following treatment for any disease: Octagam Gamunex Intratect Kiovig Gamten Panzyga Xembify Cuvitru Cutaquig Hyqvia Q3: In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases: Primary immunodeficiency (PID) Secondary immunodeficiency (SID) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Date of Response: 23/04/2026
View Response: 11347.pdf
Freedom of Information Request Reference: 11343
Date Received: 25/03/2026
Summary:
I am seeking recorded information relating to your organisation’s decarbonisation and net zero planning, with particular reference to estate energy use and Scope 1 and 2 emissions. 1) Please provide copies of your current decarbonisation, net zero or climate action plans, including any estate specific or heat decarbonisation plans (or equivalent). 2) Please provide any associated implementation plans, project pipelines or delivery road maps, including documents that set out sequencing, timelines or phasing of decarbonisation activity. 3) Please provide details of planned and/or active projects relating to: •Electricity reduction ( Scope 2) •Heat decarbonisation ( Scope 1) •On site renewable generation including where held : •Estimated Capital Cost •Forecast Energy Savings ( kWh) •Forecast Annual Financial Savings (£) •Forecast Annual Carbon savings (tCO₂e) •Estimated Payback Period. 4) Please provide any business cases, option appraisals or prioritisation frameworks used to assess and rank decarbonisation projects. 5) Please provide details of any completed decarbonisation within the last three financial years, including any evaluation of forecast versus actual performance (energy, cost and carbon savings). 6) Please confirm : •Your baseline year for carbon emissions reporting. •Your most recent reported Scope 1 and Scope 2 Emissions •Whether Scope 2 is reported on a location based and/or market-based methodology. 7) Please provide details of governance arrangements for decarbonisation delivery, including committee, board or group responsible for oversight.
Date of Response: 24/04/2026
View Response: 11343.pdf
Freedom of Information Request Reference: 11342
Date Received: 31/03/2026
Summary:
1. How many general practices or within the health board provide respiratory diagnostic tests such as a) spirometry and b) fractional exhaled nitric oxide tests. 2. How many general practices refer patients to community health centres or hubs (excluding secondary care such as hospitals) for respiratory diagnostic tests such as a) spirometry and b) fractional exhaled nitric oxide tests. 3. Name each community health centre or hub that provides respiratory diagnostic tests and list the cluster of general practices that are in the boundary of each centre/hub.
Date of Response: 22/04/2026
View Response: 11342.pdf
Freedom of Information Request Reference: 11341
Date Received: 31/03/2026
Summary:
1. What was the total qualified podiatry workforce in your Health Board on a full time equivalent (FTE) basis on 1st March 2025, including bandings? 2. What was the total qualified podiatry workforce in your Health Board on a full time equivalent (FTE) basis on 1st March 2026? 3. Within the Podiatry department in your Health Board what number of vacancies were there on 1st March 2026, and for which bandings? 4. How many roles within the Podiatry department in your Health Board have been advertised from 1st March 2025 to 1st March 2026, and at which bandings? 5. Within the Podiatry department in your Health Board how many applications did you receive per post advertised between 1st March 2025 to 1st March 2026 6. Within the Podiatry department in your Health Board of the posts advertised between 1st March 2025 to 1st March 2026 how many received no applications? 7. Within the Podiatry department in your Health Board of the posts advertised between 1st March 2025 to 1st March 2026, how many roles were you unable to appoint?  Please give reason, if known. 8. Within the Podiatry department in your Health Board of the posts advertised between 1st March 2025 to 1st March 2026 which banding it is your Health Board having the most difficulty to recruit qualified podiatrists to? 9. How many podiatrists left the Health Board between 1st March 2025 to 1st March 2026 (Please specify WTE and bandings) 10. Of those who left your Health Board between 1st March 2025 to 1st March 2026 specify their reason for leaving i)  Retirement ii) Change of career iii) Private practice iv) Other
Date of Response: 23/04/2026
View Response: 11341.pdf
Freedom of Information Request Reference: 11338
Date Received: 31/03/2026
Summary:
• What is the average wait time for being referred to sleep medicine (or whichever department/team deals with sleep apnoea)? I am under the assumption is 34 weeks for urgent cases, please confirm. What is it for non-urgent cases? • What private sleep clinics do they accept the assessment/diagnosis of? I understand that not all private clinics are accepted by the NHS depending on the condition (such as for ADHD), so I want to find out specifically which ones a patient should go to if they want the NHS to honour the private diagnosis. • If the NHS only accepts certain private clinics' input, how can a patient tell them apart from ones the NHS does not? What is the difference? Why? etc. • If a patient were to go private for part or all of the process, and drop back into the NHS for the remainder of the process, what can the patient expect from that? For example, shorter wait times as it may jump straight to treatment, or it making no difference, or making it harder to get treatment because part of the process was not through NHS, or something else entirely. • What can a patient expect if they do go private for some or all of this process with regards to it tying into the NHS? • Does going private multiple times affect getting NHS care in anyway? Many people seem to be under the impression that if you go private more than once that you are forced to opt out of all NHS care. • I'm also looking for general guidance on going private to help speed up the process
Date of Response: 30/04/2026
View Response: 11338.pdf
Freedom of Information Request Reference: 11337
Date Received: 30/03/2026
Summary:
Could I please get the number of risks identified by the infection control team across the Royal Hospital for Children and Young People over the last five years accompanied with the date identified, if a patient was moved from the room due to the issue identified and by which ward the risk was identified in.
Date of Response: 21/04/2026
View Response: 11337.pdf
Freedom of Information Request Reference: 11336
Date Received: 30/03/2026
Summary:
Please provide responses to the questions below. Programme Existence and Delivery 1. Do you currently operate a Lung Health Check / Lung Cancer Screening programme? 2. Is the programme delivered: o Directly by the NHS, or o By a third party / private sector provider? If so, who? Scanning and Equipment 1. If the programme is delivered directly by the NHS, has CT scanning equipment been purchased to support delivery of the programme? 2. How is CT scanning capacity delivered as part of the programme: o In house, o Via mobile units, or o Via a third party provider? Contractual Information 1. What is the contract start date for the Lung Health Check / Lung Cancer Screening programme? 2. What is the contract end date (or expected end date, if applicable)? 3. Who is the responsible officer or programme director for the programme? Funding 1. What is the total funding allocated to Lung Health Checks / Lung Cancer Screening in your area for the current financial year? 2. What is the source of this funding (for example: NHS England, Integrated Care Board, Cancer Alliance, or other)? Commissioning Responsibility 1. Which organisation is the commissioning body for the programme? o NHS England o Integrated Care Board (ICB) o Cancer Alliance o Other (please specify) Programme Footprint and Delivery Model 1. At what level is the programme commissioned and delivered: o ICB level, o Trust level, o Place / locality level, or o A combination of the above? Future Plans 1. Are there any current plans to expand the programme footprint or change the delivery model within the next 12–24 months? Integrated Screening 1. In light of any recent or planned ICB mergers or footprint changes, are there plans to develop an integrated screening programme (for example, combining lung screening with other screening pathways)?
Date of Response: 21/04/2026
View Response: 11336.pdf
Freedom of Information Request Reference: 11334
Date Received: 27/03/2026
Summary:
1. Please provide the total number of A&E attendances by patients of No Fixed Abode/Address due to heat related illness. Please provide data for the following time periods: •1st July 2025 – 30th September 2025 •1st July 2024 – 30th September 2024 If using SNOMED CT codes, we are interested in the following codes. If you do not use SNOMED CT coding we are happy to be guided by you on the best codes that represent heat related illnesses: •1197782006 | Hyperthermia (disorder) | •52072009 | Heat stroke (disorder) | •18615009 | Sunstroke (disorder) | •95868006 | Heat exhaustion (disorder) | •89797005 | Heat syncope (disorder) | •87108006 | Heat cramp (finding) | •55017000 | Heat edema (disorder) | •12979003 | Transient heat fatigue (disorder) | •70226007 | Heat pyrexia (disorder) | •212937007 | Heat stroke and sunstroke (disorder) |
Date of Response: 27/04/2026
View Response: 11334.pdf
Freedom of Information Request Reference: 11332
Date Received: 26/03/2026
Summary:
Please provide: Any recorded decision, report, minute or approval confirming whether the site, or any part of it, is intended to be sold or otherwise disposed of. Any recorded information showing the key decision points or approvals still required before the site can be marketed or sold. Any recorded information showing whether NHS Lothian is considering applying any conditions, restrictions or obligations to a sale of the site, including any requirements relating to future community, care or healthcare use. Any recorded information showing whether NHS Lothian has entered into or approved any exclusivity arrangement, preferred bidder arrangement, heads of terms, or similar pre-sale agreement with any third party in relation to the site.
Date of Response: 06/05/2026
View Response: 11332.pdf
Freedom of Information Request Reference: 11331
Date Received: 26/03/2026
Summary:
I understand that Surgical Site Infection (SSI) surveillance is conducted nationally in Scotland for specified mandatory procedures, including caesarean section. If possible I'd like to request the following information: •The number of caesarean section procedures performed in NHS Lothian •The number of Surgical Site Infections (SSIs) associated with these procedures SSI rates for: •Day 10 surveillance window •Day 30 readmission surveillance, if collected
Date of Response: 23/04/2026
View Response: 11331.pdf
Freedom of Information Request Reference: 11330
Date Received: 25/03/2026
Summary:
Please provide the following information: Whether NHS Lothian has had any contact, meetings, correspondence, or discussions with Palantir Technologies Inc., or any of its subsidiaries or associated companies, between 1 January 2020 and the date of this request. If so, please provide dates, attendees, and subject matter. Whether NHS Lothian has been approached by NHS England, the Department of Health and Social Care, or any UK Government body regarding adoption of the NHS England Federated Data Platform operated by Palantir Technologies. Whether any patient data held by NHS Lothian is currently accessible via, or has been shared with, the NHS England Federated Data Platform or any Palantir-operated system. Whether NHS Lothian has conducted or intends to conduct a Data Protection Impact Assessment in relation to any actual or proposed use of Palantir Technologies software or services.
Date of Response: 06/05/2026
View Response: 11330.pdf
Freedom of Information Request Reference: 11329
Date Received: 25/03/2026
Summary:
Please provide the following information for the period 1 January 2024 to 1 January 2025 most recent date available: 1. The number of patients for whom your organisation has arranged, funded, or reimbursed travel outside Scotland (including to England) for abortion services. 2. The number of patients referred to independent sector providers, such as, but not limited to, the British Pregnancy Advisory Service, for abortion care. Where possible to name the provider, please do. 3. The total annual amount paid by your organisation to independent sector providers for abortion services. If possible, please distinguish between: • Procedure/treatment costs • Administrative or contractual fees 4. The total annual cost incurred by your organisation in funding or reimbursing: • Patient travel (e.g. flights, rail, taxis) • Accommodation • Subsistence or related expenses 5. Please confirm whether your organisation centrally records: • The number of patients travelling outside Scotland for abortion care • The total cost associated with such cases
Date of Response: 24/04/2026
View Response: 11329.pdf
Freedom of Information Request Reference: 11328
Date Received: 24/03/2026
Summary:
1. Waiting times for diagnostic assessment for Alzheimer’s disease For the most recent 12 month period for which data is available, please provide: • The average, median, shortest, and longest waiting times from GP referral to initial memory clinic appointment. • The same waiting time metrics for the full pathway from: GP referral → memory clinic initial assessment → diagnostic assessment → confirmed diagnosis (where applicable). 2. Number of patients • The number of individuals referred by GPs to memory services for suspected Alzheimer’s disease in the same period. • The number who received a confirmed diagnosis. 3. Service capacity • Current staffing levels (WTE) for memory assessment services (e.g., psychology, psychiatry, specialist nurses, allied health professionals). • Any documented service pressures, backlogs, or recovery plans relating to memory assessment waiting times.
Date of Response: 29/04/2026
View Response: 11328.pdf
Freedom of Information Request Reference: 11327
Date Received: 24/03/2026
Summary:
Please can you provide the full NHS Lothian policy for shared care of ADHD medication?
Date of Response: 17/04/2026
View Response: 11327.pdf
Freedom of Information Request Reference: 11326
Date Received: 23/03/2026
Summary:
1. What Additional Pharmaceutical Care Services or Locally Enhanced Pharmaceutical Care Services are currently provided by community pharmacies in NHS Lothian. Please include any services which are not commissioned as part of the nationally negotiated pharmacy contract 2. The number of pharmacies which have agreed to provide each service 3. The total spending (including fixed retainers and activity-based payments) for each service for the last full financial year in which it is available. If the service is provided under a block contract, please provide the annual contract value for the most recent financial year available.
Date of Response: 22/04/2026
View Response: 11326.pdf
Freedom of Information Request Reference: 11324
Date Received: 23/03/2026
Summary:
1. The length in time in weeks that adults have had to wait for a tooth extraction in a) 2024/25 and b) 2025/26. 2. The length in time in weeks that children under 18 have had to wait for a tooth extraction in a)2024/25 and b) 2025/26.
Date of Response: 21/04/2026
View Response: 11324.pdf
Freedom of Information Request Reference: 11323
Date Received: 23/03/2026
Summary:
1. What the (a) longest and (b) average waiting time has been in each year since 2023 for all new outpatients under the age of 18 for dental specialties? 2. What the (a) longest and (b) average waiting time has been in each year since 2023 for all inpatient or day case admissions under the age of 18 for dental specialties?
Date of Response: 21/04/2026
View Response: 11323.pdf
Freedom of Information Request Reference: 11322
Date Received: 23/03/2026
Summary:
Please provide the following information: - The number of Specialist Grade, Specialist Grade Specialty and Associate Specialist (SAS) dentists currently employed by the Health Board. If possible, I would be grateful if you could also include: •A breakdown by service area or department •Whether these posts are full time or part time
Date of Response: 20/04/2026
View Response: 11322.pdf
Freedom of Information Request Reference: 11321
Date Received: 23/03/2026
Summary:
My request relates to "never events" or "wrong-site operations" - described as a medical error where a procedure is performed on the wrong patient, the wrong body part, or the wrong side of the body. Could you please provide the number of these incidents recorded and, where possible, the details involved in such incidents (ie what the identified error consisted of). Could this request cover the following time periods and be broken down as such. 2025 2024 2023 2022 2021
Date of Response: 22/04/2026
View Response: 11321.pdf
Freedom of Information Request Reference: 11319
Date Received: 23/03/2026
Summary:
I’d like to request a copy of the David J Bowles & Associates Ltd (2012) report titled “Investigation into Management Culture in NHS Lothian”.
Date of Response: 17/04/2026
View Response: 11319.pdf
Freedom of Information Request Reference: 11318
Date Received: 20/03/2026
Summary:
I would be grateful if you could confirm whether your trust holds the following information, and if so, provide copies or links where available: 1. Policies and Procedures Does your trust have any formal policies, pathways, or standard operating procedures that reference the care of neurodivergent patients during labour and birth? If so, please provide copies or links. 2. Guidelines or Protocols for Staff Does your trust provide any guidance or protocols for staff relating to communication approaches, sensory adjustments, reasonable adjustments, or other supportive care for neurodivergent patients during the intrapartum period? If so, please provide copies or links. 3. Resources, Tools, or Training Materials Does your trust use any resources, tools, or training materials (e.g. visual aids, communication tools, sensory supports, or staff training resources) to support neurodivergent patients during labour and birth? If so, please provide copies, links, or a brief description.
Date of Response: 17/04/2026
View Response: 11318.pdf
Freedom of Information Request Reference: 11317
Date Received: 20/03/2026
Summary:
The previous response stated that while NHS Lothian does not routinely refer staff to private providers, the need has arisen in a "very limited number of cases" for "Treatment & Assessment". To better understand this process, please provide the following information: Selection Criteria: Provide the specific clinical or administrative criteria used by the Occupational Health and Safety Service to determine when a staff member qualifies for a private sector referral for "Treatment & Assessment". Internal Policy/SOP: Please provide a copy of the formal policy, guideline, or Standard Operating Procedure (SOP) that governs the referral of NHS staff to private healthcare providers via Occupational Health. Exhaustion Protocol: Does NHS Lothian require that all "out of Lothian" NHS service options be exhausted before a private referral is considered? If so, please provide the documentation or protocol that outlines this requirement. Decision-Making Authority: Please specify which role or department within NHS Lothian holds the final budget-holding authority to approve the costs associated with these private referrals, such as those listed for 2023 and 2024. Mental Health Specifics: Regarding the "Treatment & Assessment" category, please clarify if this includes referrals for secondary psychiatric or psychological input when local NHS Lothian mental health services are deemed unavailable or unsuitable for the staff member.
Date of Response: 21/04/2026
View Response: 11317.pdf
Freedom of Information Request Reference: 11316
Date Received: 20/03/2026
Summary:
1. Where, if at all, does the Health Board carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer’s Disease? Lumbar punctures carried out within the Trust itself Lumbar punctures referred elsewhere and carried out external to the Trust Trust does not carry out lumbar punctures to diagnose Alzheimer’s Disease 2. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar puncture procedures in the diagnosis of Alzheimer’s Disease. 3. How many lumbar puncture procedures to test for Alzheimer’s Disease were performed in the last three-month period for which data are available? 4. Where, if at all, does the Health Board carry out Blood Biomarker (BBM) tests for diagnosing NHS patients with Alzheimer’s Disease? Pathology laboratory within the Trust Pathology laboratory external to the Trust Trust does not test for BBMs to diagnose Alzheimer’s Disease 5. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood Biomarker tests for the diagnosis of Alzheimer’s Disease for NHS patients. Full name of Trust or organisation(s) 6. Please provide the number of BBM tests for Alzheimer’s Disease conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory. 7. Which of the following biomarker tests were used to detect Alzheimer’s Disease? pTau181 immunoassay tests pTau217 immunoassay tests 8. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for pTau181 and pTau217 immunoassay testing for Alzheimer’s Disease? 9. How many pTau181 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months? 10. Is pTau181 testing for Alzheimer’s Disease linked to, or conducted in conjunction with, clinical trials? 11. How many pTau181 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial? 12. How many pTau217 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months? 13. Is pTau217 testing for Alzheimer’s Disease linked to, or conducted in conjunction with, clinical trials? 14. How many pTau217 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial? 15. Does your organisation participate in any of the following clinical trials? READ-OUT ADAPT Other(s) please specify below: 16. Which of the following metrics are used by the Trust to measure Blood Biomarker in the diagnosis of Alzheimer’s Disease? Number of tests Number of kits Number of runs Number of units Number of patients
Date of Response: 21/04/2026
View Response: 11316.pdf
Freedom of Information Request Reference: 11314
Date Received: 19/03/2026
Summary:
Please provide the following information for your Trust/hospital site(s) for the most recent complete 12-month period available (please state the exact start and end dates used). If your data are only available at Trust level (not site level), please provide Trust-level figures and state this explicitly. 1) Surgical specialties in scope Please report data separately for each of the following specialties (use the exact labels below): a) Cardiothoracic Surgery b) General Surgery (including: breast, colorectal, endocrine, upper GI, lower GI, and transplant—kidney, liver, pancreas) c) Neurosurgery d) Oral & Maxillofacial Surgery e) ENT / Otolaryngology f) Paediatric Surgery g) Plastic Surgery h) Trauma & Orthopaedic Surgery i) Urology j) Vascular Surgery If a specialty is not provided at your Trust/hospital site(s), please record 0 for that specialty and note “not provided”. 2) Workforce (headcount) For each specialty listed above, please provide: •Number of Consultant surgeons (substantive/headcount) •Number of SAS surgeons (headcount) (i.e., Specialty Doctor and Specialist grades) Please provide headcount (not WTE). If you can only provide WTE, please state that clearly. 3) Population served Please provide the total population served by your Trust/hospital (the figure you use for planning/catchment), and specify the source/definition used (e.g., “ICS population”, “catchment population”, etc.). 4) Surgical admissions activity Please provide the total number of admissions (elective + emergency combined) to all surgical specialties in scope (i.e., the combined total across the 10 specialties listed above) for the same 12-month period. If your admissions data are recorded using a different specialty grouping, please map as closely as possible and explain any assumptions.
Date of Response: 20/04/2026
View Response: 11314.pdf
Freedom of Information Request Reference: 11313
Date Received: 19/03/2026
Summary:
Q1. Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to? Q2. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) • Myelofibrosis (ICD10 code D47.4) • Polycythaemia Vera (ICD10 code D45) • Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005) Q3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) • Momelotinib • Fedratinib Q4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with? • Hydroxycarbamide • Interferon therapy Q5. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy (First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.) Treatment First systemic therapy Received prior systemic therapy Ruxolitinib (Jakavi) Fedratinib (Inrebic) Momelotinib (Omjjara) ICO reference
Date of Response: 20/04/2026
View Response: 11313.pdf
Freedom of Information Request Reference: 11312
Date Received: 18/03/2026
Summary:
Please could I request the following information: • Total spend on Clinical Insourcing from January 2026 until present • Breakdown of the companies used and for what specialties they were used in • Total spend on Outsourcing from January 2026 until present • Breakdown of the companies used and for what specialities they were used in
Date of Response: 17/04/2026
View Response: 11312.pdf
Freedom of Information Request Reference: 11311
Date Received: 18/03/2026
Summary:
For each year that the data has been collected, up until the most recently available complete year of data, I would like to know: 1) How many patients under the care of the gender clinic died 2) How many of these patients died by suicide or suspected suicide 3) The number of patients in 2) broken down into those patients who were a) on the waiting list for a first appointment with the gender clinic b) had had their first appointment at the gender clinic and c) had been referred by the gender clinic on to endocrinology or for surgery.
Date of Response: 17/04/2026
View Response: 11311.pdf
Freedom of Information Request Reference: 11310
Date Received: 18/03/2026
Summary:
1. How many patients are currently on the West Lothian Adult Neurodevelopmental disorders waiting list? 2. How many clinicians are currently available to provide appointments for patients waiting on the West Lothian Adult Neurodevelopmental disorders Service waiting list as of March 2026? 3. What is the Speciality breakdown of clinical staff currently providing appointments for patients waiting on the West Lothian Adult Neurodevelopmental disorders Service waiting list as of March 2026. Broken down by numbers of staff from each clinical speciality category? 4. What is the average wait for a patient from the point of being added to the West Lothian Adult Neurodevelopmental disorders waiting list to first appointment with a clinician? 5. Since patients were informed of a review of the West Lothian NDD list in September 2025 what percentage of those on the waiting list have been contacted to confirm they wish to remain on the list as of March 2026? 6. Can you confirm that NHS Lothian / West Lothian Health and Social Care Partnership are continuing to give appointments to adults referred to the NDD waiting list who have been referred for ADHD-only assessments and there has been no pause in the provision of appointments in order to only prioritise those with co-occurring mental health conditions. 7. How many patients on the West Lothian Adult Neurodevelopmental disorders waiting list have received an ADHD only assessment, in the last 12 months, to March 2026.
Date of Response: 28/04/2026
View Response: 11310.pdf
Freedom of Information Request Reference: 11308
Date Received: 17/03/2026
Summary:
Please provide the following information on NHS chaperone policies, training and reporting: 1) Current chaperone policy or policies relating the use of formal and informal chaperones. 2) Associated procedures & guidelines including: a) Guidance on how the offer, acceptance, or refusal of a chaperone must be recorded in patient notes. b) Guidance on how the sex of the chaperone is recorded. 3) If your policy/procedures/guidelines have been withdrawn, please provide: a) the most recent version. b) the date it was placed under review or withdrawn. c) the communications with staff when it was put under review or withdrawn. d) the timetable for development and approval of any replacement policy e) details of internal and external consultation lists. 4) If not included in the policy/procedures/guidelines, please also disclose: a) training and competency standards for staff acting as formal chaperones. b) training description and provision for chaperones (eg online, in person, what organisations delivers the training and outline). 5) Audit reports, quality assurance reviews, compliance monitoring, and management and/or board reports relating to chaperoning 2024 to date. 6) Related equality impact assessments (EIAs) if separate 7) Datix reports: a) Number of Datix reports raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by sex of patient and chaperone & definition of sex field in Datix. b) If you record this data by gender, please disclose the Number of Datix reports raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by gender of patient and chaperone and definition of gender field in Datix. 8) Concerns: a) Number of concerns raised by chaperones, if not recorded via Datix, in 2024, 2025 and 2026 Jan & Feb, by sex of patient and chaperone & definition of sex field. b) If you record this data by gender, please disclose the number of concerns raised by chaperones in 2024, 2025 and 2026 Jan & Feb, by gender of patient and chaperone and definition of gender field. 9) Complaints: a) Number of complaints raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by sex of patient and chaperone & definition of sex field in your complaints system. b) If you record this data by gender, please disclose the number of complaints raised related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by gender of patient and chaperone and definition of gender field in your complaints system. c) Number of Freedom to Speak Up reports related to chaperones in 2024, 2025 and 2026 Jan & Feb by sex of the reporter. d) If you record this data by gender, please disclose the number of cFTSU reports related to chaperoning in 2024, 2025 and 2026 Jan & Feb, by gender of the reporter.
Date of Response: 01/05/2026
View Response: 11308.pdf
Freedom of Information Request Reference: 11307
Date Received: 17/03/2026
Summary:
I request disclosure of the following information relating to Quail AI tool for complaints in Healthcare. I would be grateful if you could answer the following: Implementation and Usage • Has your organisation implemented or piloted the Quail AI tool for complaints handling? • If yes: o Date of implementation o Scope of use (e.g. departments, complaint types, Trust-wide or pilot) 2. Accuracy and Quality Assurance • What measures are in place to assess the accuracy of Quail-generated responses? • Has your organisation conducted any formal evaluation or audit of the accuracy or quality of letters generated using Quail? • If so, please provide: o Results of such evaluations o Any internal reports, audits, or summaries 3. Human Oversight and Editing • What percentage of Quail-generated complaint responses require: o Minor edits o Significant edits o Complete rewriting • Are clinicians or complaints staff required to review all AI-generated responses before they are sent? 4. Impact on Complaints Handling • Has the use of Quail: o Reduced complaint response times? If so, by how much (average time reduction)? o Improved response rates or compliance with statutory timelines? o Reduced workload for complaints teams or clinicians? 5. Service User Feedback • Has your organisation received any feedback from patients or service users regarding AI-generated complaint responses? • If so, please provide: o Themes of feedback o Number of complaints or concerns raised about AI-generated responses 6. Clinical and Investigative Quality • Has the use of Quail impacted: o The quality of investigations? o The quality of clinical input within complaint responses? • Please provide any available evidence, reports, or internal assessments. 7. Governance, Risk, and Safety • What governance processes are in place to oversee the use of AI in complaints handling? • Have any risks, incidents, or concerns been identified relating to: o Accuracy o Patient safety o Miscommunication • If so, please provide details (anonymised where appropriate). 8. Data Protection and Information Governance • What data protection impact assessments (DPIAs) or information governance reviews have been completed in relation to Quail? • Please provide copies or summaries of these assessments. 9. Costs and Procurement • What is the cost of implementing and using Quail (including licensing, training, and ongoing costs)? • Please provide details of the procurement process and supplier. 10. Future Plans • Does your organisation plan to: o Continue using Quail? o Expand its use (e.g. incident reporting modules)? • Please provide any available business cases or strategy documents.
Date of Response: 16/04/2026
View Response: 11307.pdf
Freedom of Information Request Reference: 11306
Date Received: 17/03/2026
Summary:
I would be grateful if you could provide the following documents or information: 1. Any Standard Operating Procedures (SOPs), operational policies, or local protocols that specifically refer to the identification, assessment, or support of carers by the Rapid Response Team. 2. Any formal referral pathways or checklists used by the RRT to signpost carers to third-sector organizations or local authority support services. 3. Any service specification or operational guidance that outlines the expected input or interventions carers should receive from the RRT during a crisis episode.
Date of Response: 16/04/2026
View Response: 11306.pdf
Freedom of Information Request Reference: 11305
Date Received: 17/03/2026
Summary:
Q1. Does your Trust treat patients for Lupus Nephritis? (ICD-10 Code: M32.14 SNOMED Code: 68815009) If the Trust doesn’t treat patients for Lupus Nephritis, to which Trust does the Trust refer patients on for treatment? Q2. How many patients have a current diagnosis of Lupus Nephritis? Please can you look at the last three full calendar years of data (2023, 2024, 2025) and provide a total number of patients who had a diagnosis in each year (ICD-10 Code: M32.14 SNOMED Code: 68815009). Q3. How many patients have received treatment in the latest four-month period (November 2025 to February 2026 if available) for Lupus Nephritis with the following treatments regimens? (ICD-10 Code: M32.14 SNOMED Code: 68815009) •Standard Therapy (Steroids + Mycophenolate Mofetil (MMF)) •Cyclophosphamide (EuroLupus regimen) •Belimumab (Benlysta) •Voclosporin (Lupkynis) •Obinutuzumab (Gazyvaro) •Ritixumab (MabThera or biosimilars) •Rituximab (any other brand) •Any other targeted therapy (please state if possible)
Date of Response: 28/04/2026
View Response: 11305.pdf
Freedom of Information Request Reference: 11300
Date Received: 16/03/2026
Summary:
I am writing to request data on your trust’s pharmacy workforce for each of the financial years from 2020/2021 to 2024/2025 under the Freedom of Information Act. Please provide the data in the below tables, if possible: 1. Total number of pharmacy staff for each year, including headcount and full-time equivalent (FTE) 2. Pharmacy workforce by agenda for change band, including headcount (HC) and full-time equivalent (FTE)
Date of Response: 28/04/2026
View Response: 11300.pdf
Freedom of Information Request Reference: 11299
Date Received: 13/03/2026
Summary:
We are looking for information on your registered nurse (band 5 and above) bank shifts. If possible, please exclude midwifery staff from any data you send. 1. Please tell us - how many bank shifts were worked at your trust by registered nurses during the periods below. Please set out these shifts by Agenda for Change (AfC) pay band, if possible 2. Please tell us – the total amount spent by your trust on bank shifts worked by registered nurses during the periods below. Please set out the amounts spent by Agenda for Change (AfC) pay band, if possible. If it is not possible to provide this by band, please give the total amount 3. Does your organisation offer a variety of registered nurse bank shifts at different pay bands (such as in tables above) or does it instead adopt a ‘flat rate’ per hour that all bank nurses would receive? (i) If it adopts a ‘flat rate’ please detail what the hourly rate is for all registered nurses. E.g: £15.88 hourly rate 4. Have there been any changes to your bank shift policy for registered nursing staff since January 2024? If so, please explain what these changes were.
Date of Response: 20/04/2026
View Response: 11299.pdf
Freedom of Information Request Reference: 11298
Date Received: 13/03/2026
Summary:
1. Please provide the overall spend so far on agency non-clinical staff in each financial year since 2022-23. Please break this down by job type e.g. admin, facilities etc 2. Please provide the overall spend so far on bank non-clinical staff in each financial year since 2022-23. Please break this down by job type e.g. admin, facilities etc
Date of Response: 20/04/2026
View Response: 11298.pdf
Freedom of Information Request Reference: 11297
Date Received: 13/03/2026
Summary:
1. How many attendances have there been at the GP walk-in centre which has opened in your health board? Please break this down by week. 2. So far, what is the estimated cost of setting up the walk-in centre in your health board? Please provide as much detail as possible. 3. How many staff members are working in these centres? Please break this down by occupation type, e.g. GP, receptionist etc
Date of Response: 20/04/2026
View Response: 11297.pdf
Freedom of Information Request Reference: 11296
Date Received: 13/03/2026
Summary:
Q1. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Zolbetuximab (Vyloy) • Any other systemic anti-cancer therapy • Palliative care only Q3. How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Zolbetuximab (Vyloy) • Any other systemic anti-cancer therapy • Palliative care only Q4. If you have been unable to answer any of the above questions because you do not treat Gastric or Gastro-Oesophageal Cancer, to which site do you refer patients that require either treatment?
Date of Response: 13/04/2026
View Response: 11296.pdf
Freedom of Information Request Reference: 11292
Date Received: 11/03/2026
Summary:
Of that yearly cohort, how many experienced a spinal cord injury as a result of their surgery (or as a result of post op complications) - includes but not limited to ischaemia of the spinal cord.
Date of Response: 20/04/2026
View Response: 11292.pdf
Freedom of Information Request Reference: 11290
Date Received: 11/03/2026
Summary:
Can I request the following, broken down by the calendar years 2019, 2023, 2024 and 2025 (most recent): 1. The median wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to the child or young person who is unwell, listen to their symptoms and decide on how to help them, and the start of treatment. 2. The longest wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to the child or young person who is unwell, listen to their symptoms and decide on how to help them, and the start of treatment.
Date of Response: 21/04/2026
View Response: 11290.pdf
Freedom of Information Request Reference: 11289
Date Received: 11/03/2026
Summary:
I would like to request a review of this FOI response as I have FOI'd every Health Board in Scotland this request - and other than a delayed apology from Grampian - I have been able to get the data from every other one. I would be quite surprised that Lothian does not follow the same data gathering rules when regarding Child Dentistry as the other health boards.
Date of Response: 16/04/2026
View Response: 11289.pdf
Freedom of Information Request Reference: 11274
Date Received: 09/03/2026
Summary:
Please provide the following information for the most recent five financial years available, or the maximum period available if five years is not readily retrievable. 1. Total number of reported MRI-related adverse events or safety incidents within your Trust. 2. Where recorded, a breakdown of incidents by category. If available, examples may include: o Patient burns during MRI scanning o Projectile incidents involving ferromagnetic objects o Non-MRI compatible equipment taken into the MRI scanner room (Zone IV) o Damage to the MRI scanner or associated equipment o MRI quench events o Adverse events related to implants or devices o Patient injury or near-miss incidents relating to MRI safety If incidents are recorded using different or broader internal categories, please provide those categories instead. 3. Where recorded, please indicate: o The number of incidents per year o Whether the incident was classified as harm, no harm, or near miss 4. If available within existing records, please indicate whether incidents involved: o Ferromagnetic equipment or objects entering the MRI scanner room o Non-MRI compatible equipment brought into the MRI scanner room o Damage to the MRI scanner 5. Operational impact, where recorded: o Estimated scanner downtime resulting from incidents (hours or days, if recorded) o Whether the scanner required service intervention or repair o Number of MRI scans cancelled due to incidents o Number of patients rescheduled due to incidents 6. Financial impact, where recorded: o Any estimated cost of repair, servicing, or replacement o Any estimated operational cost associated with scanner downtime 7. If recorded, please indicate the incident reporting system used (for example Datix or other internal incident reporting systems).
Date of Response: 07/05/2026
View Response: 11274.pdf
Freedom of Information Request Reference: 11264
Date Received: 05/03/2026
Summary:
Question One: Do you treat patients for urothelial cancer within your trust? (Yes/No) If No, to which trust(s) do you typically refer patients for treatment? Question Two: How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Cisplatin with Gemcitabine + Avelumab (Bavencio) Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Other active systemic anti-cancer therapy Palliative care only Erdafitinib Cisplatin + Gemcitabine + Durvalumab (Imfinzi) BCG therapy Chemo-Radiation Therapy Question Three: In the Metastatic urothelial cancer setting only, how many patients in the past 3 months were treated with the following systemic anti-cancer therapies first line approaches? Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Avelumab (Bavencio) Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev) Atezolizumab (Tecentriq) monotherapy Palliative care only Other
Date of Response: 20/04/2026
View Response: 11264.pdf
Freedom of Information Request Reference: 11257
Date Received: 04/03/2026
Summary:
1) Whether your organisation’s policies, contractual terms, or internal procedures require an explicit outcome based warranty or guarantee that personal data on a specific storage device has been rendered irrecoverable as a final data state following software based erasure. 2) Where software based erasure of storage media is undertaken internally, what recorded evidential assurance is relied upon to conclude that the final data state of the specific storage device is irrecoverable, as distinct from confirmation that an erasure process was executed. 3) Where software based erasure is undertaken by a third party provider: a. Do the certificates or contractual documents held constitute an explicit outcome based warranty or guarantee of irrecoverability for each specific storage device processed? b. Beyond reliance on supplier accreditation or recognised standards including but not limited to ADISA certification, ISO accreditation, NIST alignment, HMG IA standards, NHS Digital guidance, or Data Security and Protection Toolkit assertions, and beyond confirmation that a wiping process was completed, does the organisation hold any recorded, device specific documentation evidencing independent verification, testing, or validation that the data on the storage media has been rendered irrecoverable in practice? 4) If no explicit outcome based warranty or device specific outcome evidence is held beyond certification, accreditation, or confirmation of process completion, please confirm what recorded form of evidential assurance is relied upon when concluding that personal data has been rendered irrecoverable.
Date of Response: 15/04/2026
View Response: 11257.pdf
Freedom of Information Request Reference: 11255
Date Received: 04/03/2026
Summary:
I am looking for information regarding both the number of mixed-sex ward (units with overnight accommodation) at the Royal Edinburgh Hospital. As such, please provide the following information: 1. The number of mixed-sex wards 2. The type of ward i.e. whether they consist of private rooms, single-sex wards, mixed-sex wards (including bays in mixed-sex wards).
Date of Response: 21/04/2026
View Response: 11255.pdf
Freedom of Information Request Reference: 11253
Date Received: 03/03/2026
Summary:
1. Ambient Listening and Clinical Transcription Software a) What, if any, ambient listening, patient contact transcription, clinical documentation, or automated summarisation software is currently approved for use, piloted, or in active deployment within your Health Board (including GP practices)? This may include, but is not limited to, products such as: • Heidi Health (Heidi AI) • Accurx Scribe • Microsoft Dragon Medical One • Nuance Dragon Ambient eXperience (DAX) • TORTUS • Others For each product identified please state: • The clinical settings in which it is used (e.g., primary care, mental health etc) • Whether individual employees can access this as a reasonable adjustment under the Equality Act 2010? • Is the tool used to transcribe or summarise patient contacts? 2. Please provide copies of, or links to: 1) Any internal policies, guidance, or governance documentation regarding the use of ambient listening or AI-assisted clinical documentation tools 2) Data Protection Impact Assessments (DPIAs), if disclosable 3) Information governance, GDPR, or UK GDPR compliance assessments relating to: a) Cloud storage b) Data processing location (UK/EU/International) c) Third-party subprocessors d) Audio recording and transcription of patient consultations 3. Please confirm whether your Board has specific regulatory or governance requirements relating to: 1) Ambient listening technologies 2) AI-generated clinical summaries 3) Cloud-based transcription services 4) Speech-to-text and written-to-typed conversion tools used in patient care 4. Administrative or Clerical Support as a Workplace Adjustment Has your Health Board provided additional administrative or clerical assistance as a reasonable adjustment for employees with disabilities or long-term health conditions? • If so: • Is this funded internally or via Access to Work? • Is there a policy or guidance document outlining eligibility or process? Please provide anonymised aggregate data only (e.g., number of cases), not personal data. 5. Written-to-Typed Conversion Tools and Digital Note-Taking a) Has your Health Board approved or funded, either directly or via Access to Work, the use of digital handwriting-to-text devices or software, including but not limited to: • reMarkable tablet and subscription • Microsoft OneNote (with handwriting conversion) • Nebo • Other handwriting recognition or assistive note-conversion tools b) Are such tools recognised as reasonable adjustments under local policy? c) Please provide any related policy or guidance documentation. 6. General Governance and Approval Pathways 1) Does your Health Board maintain an approved software list for assistive technology or AI-based clinical documentation tools? 2) What is the process for an individual employee to request approval for new assistive or AI-based documentation software?
Date of Response: 04/05/2026
View Response: 11253.pdf
Freedom of Information Request Reference: 11250
Date Received: 03/03/2026
Summary:
I would like to request the following data: 1. The total number of live births recorded at your trust for the year 2025 2. The total number of stillbirths recorded at your trust for the year 2025 (Stillbirths as defined by the Office for National Statistics: a baby born after 24 weeks of pregnancy showing no signs of life.) 3. The total number of neonatal deaths recorded at your trust for the year 2025 (Neonatal deaths as defined by the Office for National Statistics: The death of a liveborn baby within the first 28 days of life.)
Date of Response: 20/04/2026
View Response: 11250.pdf
Freedom of Information Request Reference: 11247
Date Received: 02/03/2026
Summary:
How many women gave birth each year between 2020 and 2025? Please detail the number for each year. How many of these women were on a ‘green pathway’ (or health board equivalent) or classed as ‘low risk’ each year between 2020 and 2025? Please detail the number for each year. How many women received a C-section to give birth each year between 2020 and 2025? Please detail the number for each year. How many people gave birth who registered as a gender different from their sex assigned at birth each year between 2020 and 2025? Please detail the number for each year. How many complaints has the health board received that reference ‘misogyny’ or ‘sexism’ in each year between 2020 and 2025? Please detail the number for each year. How many women have submitted a complaint to the health board each year between 2020 and 2025? Please display this as a percentage.
Date of Response: 06/05/2026
View Response: 11247.pdf
Freedom of Information Request Reference: 11246
Date Received: 02/03/2026
Summary:
I’d like to know how many of those Stage 2 complaints the health board is currently dealing with - up to and including 1/3/2026. How many of those Stage 2 complaints have gone beyond the 20 working days timescale for a full response? Of those (Stage 2 and which are beyond the 20 working days timescale) can you please tell me how far beyond those 20 days the longest outstanding complaint is now at? Also, could you please provide the same information for your health board’s main Accident and Emergency Hospital? Could you also tell me how many people are working on the team dedicated to resolving complaints and whether their numbers have been increased to help cope with any backlog?
Date of Response: 14/04/2026
View Response: 11246.pdf
Freedom of Information Request Reference: 11240
Date Received: 27/02/2026
Summary:
Please provide the number of children and young people resident in West Lothian who are waiting for a first CAMHS (Child and Adolescent Mental Health Services) appointment within NHS Lothian who have been waiting: • Over 18 weeks, and • Over 52 weeks I request that this information covers the period from 1 January 2025 to present, and is broken down by month where possible. If residency-based data is not held, please advise what equivalent locality-based CAMHS data is available.
Date of Response: 21/04/2026
View Response: 11240.pdf
Freedom of Information Request Reference: 11235
Date Received: 27/02/2026
Summary:
Under the Freedom of Information Act 2000 I am requesting the following information regarding the Chalmers Clinic, A copy of the consent agreement form signed by patients when they are prescribed cross sex hormones.
Date of Response: 21/04/2026
View Response: 11235.pdf
Freedom of Information Request Reference: 11227
Date Received: 25/02/2026
Summary:
1. How many weekly GPs shifts / Full time equivalent GPs are engaged in the first of the GP walk-in centres opened today? 2. From where were the GPs recruited / moved to make up this complement of shifts? 3. How many GPs are appointed on a full time (more than 6 month) basis for this GP walk-in centre? 4. How many GP shifts will be used in the first year of these centres? 5. From where will the GPs be recruited? 6. How many GPs have already been engaged for the 14 centres?
Date of Response: 01/05/2026
View Response: 11227.pdf
Freedom of Information Request Reference: 11220
Date Received: 25/02/2026
Summary:
Please provide details of all the occasions on which wards, departments or services at hospitals and other sites operated by your NHS Scotland board have been temporarily or permanently closed due to flooding caused by external weather events e.g. heavy rainfall, river flooding etc., over the period 2021/22 to 2025/26. Specifically, please provide the following information in a spreadsheet format: • Site name (e.g. hospital) • Name of ward/department/service that was affected • Length of closure • Dates of closure I realise that the 2025/26 data will be incomplete, but please provide information for 2026 up to 24 February.
Date of Response: 20/04/2026
View Response: 11220.pdf
Freedom of Information Request Reference: 11219
Date Received: 24/02/2026
Summary:
1. The current number of children waiting for a neurodevelopmental assessment. 2. For those children currently waiting: a. The average time which they have been on the waiting list. b. The longest time a patient currently on the waiting list has been there. 3. The currently expected waiting time for new referrals. If it is not possible to provide this measure, please provide any other broadly equivalent measure of waiting times which might be available. 4. Whether the health board currently offers neurodevelopmental assessments to adults, and if so equivalent figures as requested in points 1, 2 and 3.
Date of Response: 20/04/2026
View Response: 11219.pdf
Freedom of Information Request Reference: 11214
Date Received: 24/02/2026
Summary:
1) Of those children and young people who started treatment at CAMH services in 2025-26, how many waited (i) 12 months, (ii) 13 months, (iii) 14 months, (iv) 15 months, (v) 16 months, (vi) 17 months, (vii) 18 months, (viii) 19 months, (ix) 20 months, (x) 21 months, (xi) 22 months, (xii) 23 months, (xiii) 24 months or more, to start their treatment following a referral. 2) What was the longest (number of days) any child or young person who started treatment at CAMH services in 2025-26 waited to begin their treatment following a referral. 3) Of those children and young people currently waiting to start treatment at CAMH services, how many have been waiting (i) 12 months, (ii) 13 months, (iii) 14 months, (iv) 15 months, (v) 16 months, (vi) 17 months, (vii) 18 months, (viii) 19 months, (ix) 20 months, (x) 21 months, (xi) 22 months, (xii) 23 months, (xiii) 24 months or more, to start their treatment following a referral. 4) What is the longest (number of days) any child or young person currently waiting to start treatment at CAMH services has been waiting to begin their treatment following a referral.
Date of Response: 20/04/2026
View Response: 11214.pdf
Freedom of Information Request Reference: 11213
Date Received: 24/02/2026
Summary:
I am writing to request an internal review of Lothian NHS Board's handling of my FOI request 'Subnational planning'. I am requesting an internal review, with particular focus on the public interest test, which I think has overlooked some important points in favour of disclosure. Given this has been headline news, it is absolutely inappropriate to withhold all information under Section 30. I believe that the exemption you have applied refers to some, but not all, of the information I requested. Therefore I am requesting an internal review of your previous response and, should the exemption be upheld, would be grateful if you could provide the rest of the information.
Date of Response: 29/04/2026
View Response: 11213.pdf
Freedom of Information Request Reference: 11200
Date Received: 20/02/2026
Summary:
Please provide the data broken down by year and for the current year to date (2025/26): 1 - The Median, Mean, and 90th Percentile wait times (in weeks) from 'Decision to Treat' to 'Date of Procedure' for: a) Patients categorized as Urgent. b) Patients categorized as Routine. 2 - The total number of patients added to the waiting list for this procedure in each of those years, categorized by priority (Urgent vs. Routine). 3 - The percentage of patients in each priority category who were treated within the 12-week legal Treatment Time Guarantee for each year. 4 - The number of patients currently on the ongoing waiting list for this procedure as of the latest available date in 2026, broken down by priority.
Date of Response: 21/04/2026
View Response: 11200.pdf
Freedom of Information Request Reference: 11193
Date Received: 18/02/2026
Summary:
For each calendar year from 2000 to the most recent complete year, and for each NHS Health Board / region where available, please provide the following aggregate statistics — no individual patient identifiers are requested: 1. Diagnostic Metrics a) Annual number of patients with a pineal cyst recorded on MRI (ICD-10 D35.4 or local equivalent). b) Annual number of patients with a pineal gland lesions (all types) b) If available, annual count of all brain MRI scans performed. 2. Neurosurgery Referrals & Consultations a) Annual number of neurosurgery referrals for patients with a recorded pineal cyst diagnosis. b) Annual number of neurosurgery outpatient attendances for pineal cyst diagnoses. 3. Surgical Interventions a) Annual counts of surgical procedures for pineal cysts. b) Annual counts of surgical procedures for all pineal region lesions (including cysts and other pathology). c) Procedure classification codes (e.g., OPCS codes) used for these surgical treatments, if routinely recorded. d) counts of A&E admissions of patients with Pineal Cysts e) average waiting time for a scheduled pineal area lesion surgery (if possible broken down detailing type of intervention (e.g. extraction, fenestration, shunt etc. ) in each Trust 4. Co-Morbidities For patients with ICD-10 D35.4 recorded, please provide annual counts of patients also recorded with: a) Neurological conditions (broad categories using ICD-10 nervous system chapters). b) Psychiatric conditions (broad categories using ICD-10 mental/behavioural chapters). If existing aggregated summary tables of co-morbid conditions in pineal cyst patients are held, please include them. 5. Outcomes & Complications If held, please provide annual aggregated counts for patients with ICD-10 D35.4 who have recorded: a) Death where pineal cyst is listed as a cause or contributing cause. b) Cyst rupture events recorded. c) Internal cyst bleeding / haemorrhage recorded. d) Aseptic meningitis recorded. e) Secondary parkinsonism recorded. f) any other co morbidity recorded. 6. Most up to date relevant patient information leaflets/brochures/web pages being provided to the patients about the diagnosis of pineal cyst, treatment pathways, risks disclosure and patients' rights information 7. Most up to date relevant radiological and treatment pathway guidelines for pineal cysts and differentiation diagnostic pathways and guidelines between pineal cysts and other tumours of pineal gland 8. Any available information about number of Neurosurgeons trained in operating on pineal area lesions per each Trust
Date of Response: 30/04/2026
View Response: 11193.pdf
Freedom of Information Request Reference: 11188
Date Received: 17/02/2026
Summary:
FOI request for how many complaints have been upheld within NHS Lothian over the last five years and how many have been not upheld.
Date of Response: 16/03/2026
View Response: 11188.pdf
Freedom of Information Request Reference: 11187
Date Received: 18/02/2026
Summary:
Please provide total amount NHS Lothian has spent each year, from 2015 to 2025, on commissioning patient procedures from other hospitals- both NHS and private- to help reduce waiting lists. A figure by each year will be sufficient.
Date of Response: 20/04/2026
View Response: 11187.pdf
Freedom of Information Request Reference: 11185
Date Received: 17/02/2026
Summary:
1.1 How many whole time equivalent histopathology consultants (as defined by being on the GMC specialist register for pathology) were employed by the trust as of 31/12/25 1.2 Of these, how many WTE posts were: • Substantive consultants • Long term locum consultants (contracts ≥3 months) • Other medical staff undertaking consultant level histopathology reporting (please specify grade) 2. How many histology cases were reported for patients treated by the Trust in the period, overall and by the following sub specialties: • Dermatology • Gastro intestinal • Genitourinary • Gynaecology • Breast • Oral • Head and neck • Other (please specify if possible) • Total histology cases reported 3. Of the total histology cases reported in the period, please give the percentage that were reported as: a. General histopathology (non subspecialist service) b. Sub specialist histopathology 4. How many of the total cases given above were reported by: a. Consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs. b. Consultants employed by the authority, being paid additional amounts over and above their salary for additional work. c. Locum consultants working for the authority d. External reporting companies. 5. Please provide the total number of cases for each of the following providers, and for each provider the number of cases reported in the period, broken down by type of work: broken down by Pre-prepared material (glass) and/or Lab services (sample or block) a. Unilabs b. HCA Laboratories including their subsidiary Backlogs c. Source LD Path (previously Source Bioscience, and LD Path limited) d. Cellular Pathology Services Limited e. Diagnexia f. Digital Pathology Partners g. Cyted (including their subsidiary Pathognomics) h. Poundbury Cancer Institute i. Medica j. Other provider (please specify) k. External reporting companies total 6. Please provide a total spend in GBP with each of the following in relation to the reporting of histology cases: a. Consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs. (salary plus NI plus pension contribution) b. Consultants employed by the authority, being paid additional amounts over and above their salary for additional work. c. Locum consultants working for the authority d. External reporting companies. e. Unilabs f. HCA Laboratories including their subsidiary Backlogs g. Source LD Path h. Cellular Pathology Services Limited i. Diagnexia j. Digital Pathology Partners k. Cyted (including their subsidiary Pathognomics) l. Poundbury Cancer Institute m. Medica n. Other provider (please specify) 7. How many vacancies does the Trust currently have for consultant pathologists and in what sub-specialities are these vacancies. If “general” please state.
Date of Response: 21/04/2026
View Response: 11185.pdf
Freedom of Information Request Reference: 11181
Date Received: 16/02/2026
Summary:
Please provide the following information: 1. A list of all surgical skin markers currently used in your organisation for: • Pre-operative site marking in theatres. • Marking the skin for bedside or ward-based procedures (e.g., central venous access, chest drains, skin demarcation, or similar). 2. For each marker, please include: • Brand and product name. • Ink colour(s). • Typical clinical area(s) where it is used. 3. Copies of any product specifications, catalogues, or procurement documents held by the organisation that describe available colours and intended use. 4. Copies of any current Organisational policies, protocols, guidelines, or training materials that: • Refer to the choice of surgical skin marker colour. • Refer to visibility of markings in different clinical contexts or patient groups. • Address this issue within equality, diversity and inclusion, patient safety, or clinical governance documents. 5. Information on whether any additional or alternative marker colours (beyond standard ones) are available within the organisation (e.g., for use in clinical areas or patient groups where standard markings may be less visible). 6. Anonymised, aggregated incident reports, risk assessments, or patient safety reports (1 January 2019 to present) where visibility of skin markings was identified as a contributory factor. (No patient-identifiable information is requested.)
Date of Response: 25/03/2026
View Response: 11181.pdf
Freedom of Information Request Reference: 11131
Date Received: 04/02/2026
Summary:
a) How many patients have been diagnosed with Non-Muscle-Invasive Bladder Cancer (NMIBC) in your Trust the past 12 months? All Bladder Cancer Patients (C67) Non-Muscle-Invasive Bladder Cancer (NMIBC) Carcinoma in situ of the bladder (D0.9.0) b) How many patients with Bladder Cancer are currently taking Bacillus Calmette-Guerin (BCG) therapy that was initiated by the Urology department? c) How many patients with Bladder Cancer are currently taking Bacillus Calmette-Guerin (BCG) therapy that was initiated by the Oncology department? d) How many patients with Bladder Cancer are currently taking Bacillus Calmette-Guerin (BCG) therapy that was initiated by a department other than Urology or Oncology department? e) Which healthcare specialty is responsible for the prescribing of Bacillus Calmette-Guerin (BCG) to patients with Bladder Cancer? Healthcare Specialty Oncologist Urologist Specialist Oncology Nurse Specialist Urology Nurse Other please specify f) Which healthcare specialty is responsible for the administration of Bacillus Calmette-Guerin (BCG) to patients with Bladder Cancer? Healthcare Specialty Oncologist Urologist Specialist Oncology Nurse Specialist Urology Nurse Other please specify g) How many patients with Bladder Cancer have been BCG-unresponsive in the past 12-months? BCG-unresponsive h) How many patients with Bladder Cancer have received a combination therapy of BCG + Interferon + Gemcitabine in the past 12-months? BCG + Interferon + Gemcitabine i) How many trans-urethral resection of bladder tumour (TURBT) procedures have been carried out in the past 12-months (OPCS code M32.6)? Trans-urethral resection of bladder tumour (TURBT) procedures j) How many of the following cystectomy procedures in patients with Bladder Cancer have been carried out in the past 12 months? Procedure Code Procedure Description M34.3 Cystectomy NEC M34.4 Simple cystectomy k) Please provide a list of other Trusts or organisations that you refer patients to for Cystectomy l) How many of the following bladder procedures have been carried out in the past 12 months? Procedure Code Procedure Description M49.4 + X72.2 Intravesical instillation of MMC 49.4 + X72.2 Intravesical instillation of BCG M49.4 Intravesical instillation of IAluril/Cystistat M42.3 + Y08.4 Laser ablation of bladder tumour (TULA)
Date of Response: 01/05/2026
View Response: 11131.pdf
Freedom of Information Request Reference: 11121
Date Received: 02/02/2026
Summary:
Can you release stillbirth and neonatal death numbers by hospital/unit and year (last 10 years), including cause categories where recorded. For a defined recent period (e.g. 5 years): • Stillbirth and neonatal death rates broken down by SIMD quintile and ethnicity. • Any internal analyses of inequalities in outcomes, and action plans to address them. • Any local board level copies of HIS inspection self assessments for maternity “safe delivery of care” inspections, if not already published.
Date of Response: 06/05/2026
View Response: 11121.pdf
Freedom of Information Request Reference: 11120
Date Received: 02/02/2026
Summary:
Can you release: Waiting time data for perinatal mental health assessments and treatment (psychology/psychiatry) for women referred from maternity services, broken down by year and by board, for the last 5 years. Any screening tools or thresholds used in maternity services to identify post natal PTSD, PND or severe anxiety, plus numbers screened and numbers referred. Any internal audits, surveys or staff side reports on “birth trauma” and its psychological impact, including references to staffing levels, “compassion fatigue” or burnout
Date of Response: 28/04/2026
View Response: 11120.pdf
Freedom of Information Request Reference: 11118
Date Received: 02/02/2026
Summary:
Can you release: • Copies of current and historic (from 2011 onwards) guidelines on: • Maternal request Caesarean section (MRCS). • “Normal birth” / “active birth” / “physiological birth” promotion and any targets for vaginal/“normal” birth rates. • Annual data (last 5–10 years), by unit where possible: • Total births, total Caesareans, elective vs emergency Caesareans. • Number of MRCS carried out, and number of maternal requests declined. • For women whose MRCS request was declined, the eventual mode of birth (unassisted vaginal, instrumental, emergency Caesarean). Any internal audits, minutes or briefing papers that: • Discuss reducing Caesarean rates / increasing “normal birth” rates. • Refer to targets, dashboards or performance measures on mode of delivery. • Copies of patient information leaflets given at 16 and 36 weeks about birth options, and any internal instructions about completing “promoting normal birth” documentation.
Date of Response: 07/05/2026
View Response: 11118.pdf
Freedom of Information Request Reference: 11114
Date Received: 30/01/2026
Summary:
1. The number of Emergency Detention Certificates (EDCs) granted in NHS Lothian, since January 2021, broken down by clinical specialism of the registered medical practitioner who granted the EDC 2. The number of Emergency Detention Certificates (EDCs) granted in NHS Lothian without Mental Health Officer (MHO) consent, since January 2021, broken down by clinical specialism of the registered medical practitioner who granted the EDC 3. Any (a) data, (b) correspondence and (c) analysis held by NHS Lothian since January 2021 demonstrating how the Board met obligations under Section 36 of the Mental Health (Care and Treatment) (Scotland) Act 2023 which requires that medical practitioners consult and receive consent from a Mental Health Officer (MHO) before granting an Emergency Detention Certificate (EDC). 4. Any (a) data, (b) correspondence and (c) analysis held by NHS Lothian since January 2021 regarding the reasons that medical practitioners have been unable to gain MHO consent before granting an Emergency Detention Certificate (EDC) aggregated or categorised as appropriate to prevent the identification of individuals. 5. Any information held since January 2021, including (a) minutes and (b) meeting papers covering the topic of Mental Health Officer (MHO) consent for Emergency Detention Certificates (EDCs) arising from end of year meetings between NHS Lothian and the Mental Welfare Commission (MWC). These meetings are referenced in the MWC annual Mental Health Act Monitoring reports ( For example: MHA monitoring report 2024-25 page 15). 6. Copies of all audits undertaken since January 2021 by NHS Lothian on the reasons for failure to include MHO consent in Emergency Detention Certificates (EDCs). The audits are referred to in the MWC annual Mental Health Act Monitoring reports ( For example: MHA monitoring report 2024-25 page 15). 7. Any (a) training, (b) guidance or (c) policies provided or utilised by NHS Lothian, since January 2021, to support registered medical practitioners in their decision-making when considering granting an (EDC) rather than applying for a Short-term Detention Certificate (STDC).
Date of Response: 04/05/2026
View Response: 11114.pdf
Freedom of Information Request Reference: 11055
Date Received: 15/01/2026
Summary:
NEURODEVELOPMENT ASSESSMENTS 1) Pls outline the number of children currently waiting for a neurodevelopmental assessment in your health board 2) Pls outline the current median wait (in days/weeks) for the original assessment of any condition 3) Pls outline the longest waiting time (in days/weeks) for a child to get a neurodevelopmental assessment in your health board
Date of Response: 18/02/2026
View Response: 11055.pdf
Freedom of Information Request Reference: 11076
Date Received: 21/01/2026
Summary:
Please could you provide the following details regarding your Trust’s use of digital systems in the Respiratory, Neurophysiology, Obstetrics and Gynaecology, and Maternity departments: 1. Does your Trust currently use any software systems to manage clinical records, diagnostics, or workflows within Respiratory? 2. If yes, please provide: o The name of the software provider and product. o The start date and duration of the current contract. o The expiry date or next renewal date of the contract. o Whether the contract includes options for extension or renewal. 3. Does your Trust currently use any software systems to manage clinical records, diagnostics, or workflows within Neurophysiology? 4. If yes, please provide: o The name of the software provider and product. o The start date and duration of the current contract. o The expiry date or next renewal date of the contract. o Whether the contract includes options for extension or renewal. 5. Does your Trust currently use any software systems to manage clinical records, diagnostics, or workflows within Obstetrics and Gynaecology? 6. If yes, please provide: o The name of the software provider and product. o The start date and duration of the current contract. o The expiry date or next renewal date of the contract. o Whether the contract includes options for extension or renewal. 7. Does your Trust currently use any software systems to manage clinical records, diagnostics, or workflows within Maternity? 8. If yes, please provide: o The name of the software provider and product. o The start date and duration of the current contract. o The expiry date or next renewal date of the contract. o Whether the contract includes options for extension or renewal.
Date of Response: 24/04/2026
View Response: 11076.pdf
Freedom of Information Request Reference: 11248
Date Received: 02/03/2026
Summary:
In your Health Board area, do you have any inpatient Mental Health Wards where there is no on site Resident Doctor medical cover during the Out of Hours period? If so, what provision do you make if there is a medical emergency/urgent situation?
Date of Response: 16/04/2026
View Response: 11248.pdf
Freedom of Information Request Reference: 11309
Date Received: 18/03/2026
Summary:
Number of clinical biochemistry tests per below years, please: 2018-2019; 2019-2020; 2020-2021; 2021-2022; 2022-2023; 2023-2024
Date of Response: 15/04/2026
View Response: 11309.pdf
Freedom of Information Request Reference: 11302
Date Received: 16/03/2026
Summary:
i. The name of each ward. i.e. Ward 2 ii. The location of each ward. i.e. St John's Hospital iii. The speciality of each ward. i.e. Cardiology iv. The number of beds on each ward.
Date of Response: 15/04/2026
View Response: 11302.pdf
Freedom of Information Request Reference: 11301
Date Received: 16/03/2026
Summary:
1. Policies and Procedures Please provide copies of any current NHS Lothian policies, procedures, guidance documents, or frameworks that relate to: • communication related reasonable adjustments for patients, and • the assessment, approval, and implementation of such adjustments. 2. Application and Assessment Process Please provide any documents that describe: • how patients can request communication related reasonable adjustments, including people disadvantaged by, or unable to apply by phone. • how such requests are assessed, • who is responsible for making decisions, and • any criteria used in decision making. 3. Governance and Oversight Please provide documents that outline: • the governance structure for communication related reasonable adjustments, • any committees, roles, or teams responsible for oversight, and • how compliance with the Equality Act 2010 is monitored in relation to communication accessibility. 4. Internal Guidance to Staff Please provide any internal staff guidance, training materials, or operational instructions relating to: • communicating with patients who require written or alternative communication formats, and • handling requests for non telephone communication routes.
Date of Response: 15/04/2026
View Response: 11301.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate